Clinical Trial Update: Proof-of-concept Study for SAR441344 (Frexalimab) in Relapsing Multiple Sclerosis [Phase 2]

View source ↗

Summary

Phase 2 proof-of-concept trial of frexalimab (SAR441344) for relapsing-remitting multiple sclerosis; results have been posted, and the study is currently active…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Relapsing-remitting Multiple Sclerosis

Drugs mentioned

• Frexalimab (SAR441344)

Snippet

Sponsor: Sanofi | Conditions: Multiple Sclerosis | Phase 2 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2025-09-30